The British pharmaceutical company AstraZeneca, which announced today, is testing the experimental antibody cocktail in a third phase to reduce serious illness or death in untreated patients.
The drug, called AZD7442, reduces the risk of developing severe Covid-19 or the risk of death in patients who are symptomatic for seven days or less by reaching the test target.
Mene Pangalos, executive vice president of AstraZeneca, said: “Early intervention in our antibodies can significantly reduce the progression of a serious illness and protection lasts more than six months.”
The company will discuss the information with health authorities, he added.
AstraZeneca also develops an antibody cocktail as a treatment to protect people who do not have a strong enough immune response to the Covid-19 vaccine. Last week, it asked U.S. regulators for emergency permission to use it as a disease prevention drug.